Literature DB >> 16165920

Endocrine therapy for prostate cancer.

Jan-Erik Damber1.   

Abstract

Endocrine therapy of prostate cancer has mostly been reserved to patients with advanced stages of the disease. The principle for endocrine treatment of prostate cancer is elimination of stimulatory effects of testicular androgens on the prostate tumour cells. This can be achieved by surgical removal of the testes, by inhibition of pituitary gonadotrohin secretion by GnRH-angonsists or antagonists, by oestrogens or by non-steroidal antiandrogens. Since non-steroidal antiandrogens have fewer side-effects than castrational therapies, there is an increased interest for using endocrine treatment as adjuvant therapy after localized treatment. At least in certain stages of the disease, early hormonal treatment may have survival benefits. The timing of endocrine therapy, the usage of combined androgen blockade and intermittent endocrine therapy will be discussed in this overview.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16165920     DOI: 10.1080/02841860510029743

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  9 in total

1.  Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.

Authors:  Ya-Nan Man; Yan-Fang Chen
Journal:  Int Urol Nephrol       Date:  2019-08-27       Impact factor: 2.370

Review 2.  Androgens, aging, and prostate health.

Authors:  Karin Welén; Jan-Erik Damber
Journal:  Rev Endocr Metab Disord       Date:  2022-06-24       Impact factor: 6.514

Review 3.  Insights into Aptamer-Drug Delivery Systems against Prostate Cancer.

Authors:  Xueni Wang; Qian Zhou; Xiaoning Li; Xia Gan; Peng Liu; Xiaotao Feng; Gang Fang; Yonghong Liu
Journal:  Molecules       Date:  2022-05-26       Impact factor: 4.927

4.  LHRH Agonists for the Treatment of Prostate Cancer: 2012.

Authors:  Herbert Lepor; Neal D Shore
Journal:  Rev Urol       Date:  2012

5.  Silencing of LINC01963 enhances the chemosensitivity of prostate cancer cells to docetaxel by targeting the miR-216b-5p/TrkB axis.

Authors:  Zengshu Xing; Sailian Li; Jiansheng Xing; Gang Yu; Guoren Wang; Zhenxiang Liu
Journal:  Lab Invest       Date:  2022-02-12       Impact factor: 5.502

6.  Intratesticular injection of hypertonic saline : non-invasive alternative method for animal castration model.

Authors:  Byung Kuk Kwak; Sung-Ho Lee
Journal:  Dev Reprod       Date:  2013-12

7.  Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.

Authors:  Greg N Brooke; Simon C Gamble; Michael A Hough; Shajna Begum; D Alwyn Dart; Michael Odontiadis; Sue M Powell; Flavia M Fioretti; Rosie A Bryan; Jonathan Waxman; Robin Wait; Charlotte L Bevan
Journal:  Mol Cell Proteomics       Date:  2015-02-18       Impact factor: 5.911

8.  Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.

Authors:  Senmao Li; Jindong Sheng; Zhenhua Liu; Yu Fan; Cuijian Zhang; Tianjing Lv; Shuai Hu; Jie Jin; Wei Yu; Yi Song
Journal:  J Cell Mol Med       Date:  2021-01-28       Impact factor: 5.310

Review 9.  Direct Intercellular Communications and Cancer: A Snapshot of the Biological Roles of Connexins in Prostate Cancer.

Authors:  Catalina Asencio-Barría; Norah Defamie; Juan C Sáez; Marc Mesnil; Alejandro S Godoy
Journal:  Cancers (Basel)       Date:  2019-09-14       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.